These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10243913)

  • 1. The pharmacist's role as a member of the institutional review board.
    Donehew GR; Schaumberg JP
    Hosp Pharm; 1979 Sep; 14(9):508-9, 512, 515 passim. PubMed ID: 10243913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The purpose, composition, and function of an institutional review board: balancing priorities.
    Enfield KB; Truwit JD
    Respir Care; 2008 Oct; 53(10):1330-6. PubMed ID: 18811996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of human subjects: categories of research that may be reviewed by the Institutional Review Board (IRB) through an expedited review procedure--FDA. Notice.
    Fed Regist; 1998 Nov; 63(216 Pt 1):60353-6. PubMed ID: 10187395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacist involvement in institutional review of clinical trials.
    Raehl CL; Miller DE; Foster TS
    Am J Hosp Pharm; 1981 Mar; 38(3):334-9. PubMed ID: 7223743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of human subjects: Institutional Review Board; report and recommendations of National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.
    Fed Regist; 1978 Nov; 43(231):56173-98. PubMed ID: 10239683
    [No Abstract]   [Full Text] [Related]  

  • 6. The historical, ethical, and legal background of human-subjects research.
    Rice TW
    Respir Care; 2008 Oct; 53(10):1325-9. PubMed ID: 18811995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of human subjects; informed consent; standards for institutional review boards for clinical investigations--FDA. Proposed rule.
    Fed Regist; 1988 Nov; 53(218):45678-82. PubMed ID: 10290533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human subject protections in the United States: perspectives from the Office for Protection from Research Risks.
    Russell-Einhorn M; Ellis GB
    J Biolaw Bus; 1998; 1(2):36-8. PubMed ID: 12739540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to do human-subjects research if you do not have an institutional review board.
    Rice TW
    Respir Care; 2008 Oct; 53(10):1362-7. PubMed ID: 18812001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exemption of certain research and demonstration projects from regulations for protection of human research subjects--Office of the Secretary, HHS. Final rule.
    Fed Regist; 1983 Mar; 48(44):9266-70. PubMed ID: 10259812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of human subjects; standards for institutional review boards for clinical investigations--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(17 pt 2):8958-79. PubMed ID: 10249529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final regulations amending basic HHS policy for the protection of human research subjects--Department of Health and Human Services. Final rule.
    Fed Regist; 1981 Jan; 46(16 Pt 2):8366-91. PubMed ID: 10249932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research activities which may be reviewed through expedited review procedures set forth in HHS regulations for protection of human research subjects--Department of Health and Human Services. Notice.
    Fed Regist; 1981 Jan; 46(16 Pt 2):8392. PubMed ID: 10249933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expanding role of the transplant pharmacist in the multidisciplinary practice of transplantation.
    Martin JE; Zavala EY
    Clin Transplant; 2004; 18 Suppl 12():50-4. PubMed ID: 15217408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical tips for working effectively with your institutional review board.
    Schwenzer KJ
    Respir Care; 2008 Oct; 53(10):1354-61. PubMed ID: 18812000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human subject protection in clinical trials.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1997 Jan; 3(1):19-23. PubMed ID: 11363958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tales of informed consent: four years on an institutional review board.
    Bartolo
    Health Matrix Clevel; 1992; 2(2):193-245. PubMed ID: 10124879
    [No Abstract]   [Full Text] [Related]  

  • 18. Exemption of certain research and demonstration projects from regulations for protection of human research subjects--DHHS. Notice of proposed rulemaking.
    Fed Regist; 1982 Mar; 47(55):12276-7. PubMed ID: 10261479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of human subjects research: options available to the Institutional Review Board.
    Novak R
    Grants Mag; 1983 Dec; 6(4):225-31. PubMed ID: 10267354
    [No Abstract]   [Full Text] [Related]  

  • 20. Hospital institutional review board committee: a pharmacist takes a seat.
    Goll EF; Miner PL
    Pharm Pract Manag Q; 1998 Jan; 17(4):48-53. PubMed ID: 10174748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.